Use of living systems and organisms to develop or make useful products
This time on Building Biotechs: A Podcast by Recruitomics Consulting, Robert Buckley, Chief People Officer at Enveda Biosciences, joins us to talk all about why data isn't the only answer in biotechs, how to leverage data in the hiring process, how to take feedback as a gift, and training non-science people in biotechs.
In this talk originally given at the Colorado Farm Bureau, expert conversationalist and host of Legacy Interviews Vance Crowe describes the inner workings and lessons gathered from Legacy Interviews, including the value in the wisdom of our elders. -Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.
Is it time to audible on our market outlook (2:00)? The easing of financial conditions (12:00), 60/40 portfolios are having their best performance since 1991 and Barron's sounds bullish (17:30), a potential China risk in 2024 (23:00), state of the consumer & homebuilders (30:00). Later, Guy and Dan sit down with Dr. Arsani William from Logos Capital and discuss his background from clinician to investor (34:30), the focus at Logos (43:30), the interest rate impact on biotech stocks (48:00), ways to invest in the biotech sector (55:30), weight loss drugs (58:00), and how to invest in the GLP-1 craze (1:05:00). — About the Show: On The Tape is a weekly podcast with CNBC Fast Money's Guy Adami, Dan Nathan and Danny Moses. They're offering takes on the biggest market-moving headlines of the week, trade ideas, in-depth analysis, tips and advice. Each episode, they are joined by prominent Wall Street participants to help viewers make smarter investment decisions. Bear market, bull market, recession, inflation or deflation… we're here to help guide your portfolio into the green. Risk Reversal brings you years of experience from former Wall Street insiders trading stocks to experts in the commodity market. — Check out our show notes here Learn more about Ro body: ro.co/tape See what adding futures can do for you at cmegroup.com/onthetape. — Shoot us an email at OnTheTape@riskreversal.com with any feedback, suggestions, or questions for us to answer on the pod and follow us @OnTheTapePod on Twitter or @riskreversalmedia on Threads — We're on social: Follow @GuyAdami on Twitter Follow Danny Moses @DMoses34 on Twitter Follow Liz Young @LizYoungStrat on Twitter Follow us on Instagram @RiskReversalMedia Subscribe to our YouTube page
Combined Therapeutics President & CEO Dr. Romain Micol is operating his company in a very noisy space, where hundreds of new biotechs have popped up on the coattails of a COVID-driven renewal of interest in mRNA vaccines. Micol recognizes that noise and the competition it brings for capital and mindshare. He's not only aware of it — he welcomes it. On this quick episode of the Business of Biotech podcast, Micol shares the unique approach Combined Tx is taking to distinguishing itself in the mRNA infectious disease and cancer vaccine space, from the delivery, safety, efficay, and business perspectives. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
In the past decade, we've seen an explosion in medical and biotechnologies like gene editing with CRISPR, synthetic organs, cloning, and AI-powered prosthetics that are helping to eradicate disease, improve the human condition, and enhance our brain power. These developments have radically transformed our understanding of the human body and what we thought was possible. But like most new tech, there's also potential for misuse, privacy concerns, and ethical implications. Gene editing can cure debilitating diseases but also lead to designer babies. AI learning algorithms can power neural implants but also potentially create new chemical weapons. Ian Bremmer delves into that tension on the GZERO World Podcast with Siddhartha Mukherjee, a physician and biologist whose new book, “The Song of the Cell,” explores the science, history, and technology behind what he calls “the new humans.”
Earlier this week Celine Halioua (ODF2), founder and CEO of Loyal — a dog longevity biotech startup — announced something truly groundbreaking.Loyal (ODF2) has earned what they believe to be the FDA's first-ever formal acceptance that a drug can be developed and approved for lifespan extension. As Celine says in her announcement; “I started Loyal 4 years ago with the explicit goal to get the first drug FDA approved for lifespan extension itself - no disease, just healthy, longer"..."We can't start selling the drug yet - we need to complete the safety and manufacturing technical sections - but this represents the lions share of the 'existential risk' of both the drug program, and of Loyal AKA - we are doing it!!!”Laura Deming is a longevity biotech investor with an incredible batting average. 5 of 18 startups she's backed so far have gone public. She was the first investor in Loyal and had this to say:"This just dropped - the most important milestone in the history of longevity biotech. put simply, this is the FDA's first-ever formal acceptance that a drug can be developed and approved to extend lifespan. the longevity field is evolving quickly. No one I know in the field would have said this was possible 5 years ago. Celine got it done in 4. It's a massive win for both biotech founders and regulators, in establishing a pathway by which drugs (initially for dogs) can get approved for lifespan"You're about to listen to an archival interview with Celine just one and a half years into starting Loyal which is now 4 years old. It's an incredible conversation with interviewer Marshall Kosloff and shows just how much can be accomplished in a few short years.Congrats to Celine and the entire Loyal team on what is truly an unparalleled milestone.Are you exploring starting a company we've got a program for that?ODF has helped 1k companies like Loyal which was ODF2 get started and go on to raise over $2B. Applications for our 20th cohort in San Francisco are now . Learn more and apply at beondeck.comloyalfordogs.comCeline's personal websiteCeline on X/Twitterbeondeck.comOn Deck on X/Twitterpodcast episode archive and show notes
Episode Description: We dive into the dynamic intersection of biotechnology and venture capital with our guest Julie Wolf. From her transition from a microbiologist to a venture capitalist, Julie sheds light on the nuances of investing in biotech startups, the impact of synthetic biology, and the transformative role of AI in the field. Her journey paints a vivid picture of the future of biotech and its significance in shaping healthcare and beyond. This episode is a must-listen for anyone curious about the business side of biotech innovations and the future landscape of this rapidly evolving industry. Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space. Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 00:00:00 - Biotech Meets Venture Capital: An Intriguing Fusion 00:02:58 - Gene Editing: Shaping Tomorrow's Biotech 00:04:33 - Educating the Next Wave of Biotech Innovators 00:07:17 - Biotech's Boundless Future: Exploring the Possibilities 00:09:15 - Julie Wolf's Odyssey: From Microbiologist to VC Maven 00:17:54 - Bioproduction: The Heartbeat of Biotech Evolution 00:19:13 - Diverse Landscapes: A Journey Through Biotech Companies 00:22:08 - The Art of Investing in Biotech Brilliance 00:24:36 - Cancer Therapy Revolution: Biotech's Pioneering Role 00:27:59 - Awkward: A Key Player in Strengthening Biosecurity 00:29:46 - DNA Synthesis: The New Frontier in Biotech 00:31:03 - AI: The Game Changer in Biological Breakthroughs 00:32:41 - Mastering the Microscopic: AI in Cell Analysis 00:34:16 - Decoding Startup Success: Investment Insights in Biotech 00:36:45 - Leadership Evolved: The Making of Biotech Pioneers 00:38:21 - Building Biotech's Backbone: Infrastructure Innovations 00:41:01 - Entrepreneurial Wisdom: Navigating Biotech's Tides 00:43:40 - Biotech's Bright Future in the New York Ecosystem 00:48:48 - Defense & Biotech: An Unseen Alliance 00:51:07 - Customer Discovery: The Unsung Hero in Biotech Success Episode Links: LinkedIn 2048 Ventures (website) American Society for Microbiology Genspace Indiebio Coding Bio Aclid Bio Nucleate Have a question or comment? Message us here: Text or Call (804) 505-5553 Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: email@example.com Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message
The market for GLP-1s — also commonly known as obesity drugs — is projected to exceed $100 bn globally by 2030. Why are these drugs growing in popularity, and could they lead to a paradigm shift in health care? Elif Korkmaz, who covers Health Care Specialist Sales, sits down with Chris Schott, Senior Analyst covering U.S. Diversified Biopharma, and Richard Vosser, Head of European Pharma & Biotech, to discuss the latest developments in this space. This episode was recorded on Wednesday, November 29th. This communication is provided for information purposes only. Please read JP Morgan research reports related to its contents for more information including important disclosures. Copyright 2023 JP Morgan Chase & Co. All rights reserved.
In the dynamic field of life sciences, skillful operators ensure the efficient development of medical innovations, while insightful investors provide crucial capital and strategic guidance. Rich Aldrich's 30+ year career uniquely bridges both sides, having played key roles in founding and managing successful ventures in the industry.Rich Aldrich is a co-founder and partner at Longwood Fund. Before Longwood, he founded RA Capital Management and has been instrumental in co-founding and contributing to the growth of notable biotech companies, including Sirtris Pharmaceuticals, Concert Pharmaceuticals, and Vertex Pharmaceuticals, among others.In this episode, Hercules Capital's Janice Bourque and Rich Aldrich discuss key lessons in operations and investment, the advantages of public investing, the attributes of a strong management team, Rich's reflections on the industry and much more.Topics include:Transitioning from operations to investingRich's key lessons from public investmentsThe advantages of public investingAttributes of a strong management teamCurrent areas of scientific interest for RichEmerging challenges in life sciencesDeciding whether or not to commercializeRich's reflections on the industry's evolutionAnd other topics…Rich Aldrich is a co-founder and partner of Longwood Fund, an early-stage life science venture firm. With over 30 years of experience in the life sciences space, he has co-founded and helped build several biotech companies including Sirtris Pharmaceuticals, Concert Pharmaceuticals, and Vertex Pharmaceuticals, among others. Before the Longwood Fund, Rich founded RA Capital Management, a life sciences investment fund with an AUM of over $9 billion.Rich received his undergraduate degree from Boston College and an MBA from the Amos Tuck School at Dartmouth. He currently serves as a Director of Longwood portfolio companies Axial, Sitryx Therapeutics, and Colorescience.
In this ground-breaking episode of Green Beauty Conversations, we dive into the world of biotech beauty, a realm where the age-old practices of botanical extraction meet cutting-edge science. For millennia, the natural world provided the raw ingredients for cosmetics. The early 1900s brought chemistry to bear on ingredient manufacture, but now, with the massive rise in demand for all-natural beauty products, we are seeing demand for plant-extracted cosmetic ingredients outstripping supply. Factor in the costs to the natural world associated with growing, harvesting and processing plant-based ingredients, and you begin to realise that biotech could be the sustainable solution for the beauty industry. Biotech ingredients that mimic plant extracts like for like can scale, be created sustainably in a lab, reduce costs, claim efficacy and be high-performance cosmetic ingredient sources. Are we at the cusp of a massive shift to biotech in the cosmetics industry? Are we also about to see ingredient wars between the all-natural, plant-extracted camp and the biotech pioneers? Our guest, Josh Britton, CEO of Debut Biotech, guides us through the revolutionary changes biotechnology is bringing to the cosmetic industry. Join podcast host and Formula Botanica CEO Lorraine Dallmeier as she uncovers how Debut Biotech is leading the charge in this new era, transcending traditional methods to create high-performance, sustainable ingredients. To learn more about this episode, all of the links that were mentioned and anything else, please visit the show notes on the Formula Botanica website.
This time on Building Biotechs: A Podcast by Recruitomics Consulting, Lynn Walder, Founder & Principal of Executive Management Partners and Director of Partnerships Programming at LabCentral, joins us to discuss why you should never give up on your startup; whether it's better to work in a big business or a small startup; how to overcome burnout; and whether there is any such thing as work-life balance.
Scott Pilchard is an investment advisor specializing in guiding farm families through financial, retirement, and business succession planning. He addresses challenges like being land-rich but cash-poor, stressing the importance of careful planning for the family's financial future.Website: https://www.westernskiesadv.com/-Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.
Dr. Chad Briscoe Unveils the Vision - Where Bar Conversations Meet Breakthroughs in Biotech. Bringing great pharmaceutical science to the people in a light, fun, and inspirational manner.
Welcome to the premiere of BioTalk Unzipped, the podcast where the complex world of biotechnology gets unzipped by your hosts, Gregory Austin and Dr. Chad Briscoe. In this inaugural episode, we invite you to pull up a virtual chair and join us in an enlightening conversation that transcends the boundaries of traditional scientific discussions. What's on the Table? Discover the pulse of the biotech industry as we dive into the latest headlines and unravel the stories shaping the future. Gregory and Dr. Chad bring their unique perspectives to the table, shedding light on the trends and surprises that define the ever-evolving landscape of biotechnology. Meet Gregory and Chad and get a feel for their backgrounds and careers. Facing the Unknown: When Biotech Companies Fail Explore the candid dialogue as we navigate the often uncharted territory of failure in biotech companies. What happens when the best-laid plans go awry? How do setbacks contribute to the industry's overall resilience? Join us as we share insights, lessons learned, and the silver linings that emerge from the challenges. Behind the Curtain: Dr. Chad Briscoe's Biotech Revelations Join us as we delve into the riveting world of biotech surprises with none other than our co-host, Dr. Chad Briscoe. In this episode, Dr. Briscoe unveils the moments in his distinguished career that left him utterly surprised. Blueprints for Success: Navigating the Scientist's Journey Ever wondered what it takes to be a successful scientist in the fast-paced world of biotech? Gregory and Dr. Chad pull back the curtain on their own experiences, offering valuable insights, tips, and strategies for aspiring scientists. Whether you're a seasoned professional or just starting your journey, this episode is a compass for success in the field. Join the Conversation BioTalk Unzipped isn't just a podcast; it's an invitation to join a community of curious minds passionate about biotechnology. Engage with us as we unravel the complexities, share stories, and explore the fascinating intersection of great science and life. Tune in to the BioTalk Unzipped Premiere and embark on a journey through the realms of biotech that goes beyond the ordinary. Don't miss out on the conversation - because the future of biotechnology is unzipped here! To connect with the Cohosts directly, visit their LinkedIn pages: Gregory Austin - https://www.linkedin.com/in/gregoryaustin1/ Dr. Chad Briscoe - https://www.linkedin.com/in/chadbriscoe/To see Gregory Austin's book, “Stellar Resume Writing: Secrets From a Corporate Recruiter”, visit Amazon: https://www.amazon.com/dp/B07NTK6RG2 #biotechnology #pharmaceutical #science #drugdevelopment #drugdiscovery
When it comes to landing and executing strategic partnerships, Regeneron puts on a clinic. Partnerships, acquisitions, licensing agreements, and other deals large and small with Intellia, Decibel Therapeutics, BARDA, Alnylam, and Sonoma Therapeutics are just a sampling of those making news this year alone. The man behind much of that dealmaking is none other than Nouhad Husseini, SVP and Head of Business Development and Corporate Strategy at Regeneron. He's a guy who's deftly married the art and science of biopharma dealmaking, and on this episode of the Business of Biotech podcast, we're getting introspective with this legend in the making, who our friend Allan Shaw says “turns the deals he touches into gold.” Strategic dealmaking is central to the biotech business, and today's episode offers a master class. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
After 8.5 years of weekly podcasts I'm going to take a 5 week break and plan new episodes for 2024. I'm going through a medical glitch that has me unable to do my normal work. On top of this we're going to switch to an audio plus video format to find a wider audience. So check back in 2024 for the next episode. Have a great rest of 2023, thank you for listening, and looking forward to better times.
Many businesses to see AI benefits within medium term The democratization of artificial intelligence or AI has created a major tech wave for consumers. AI promises to make some businesses more efficient and even help businesses generate more revenue. We surveyed BofA Global Research analysts across the globe and found that 94% of covered companies plan to use AI to become more efficient and generate revenue. Survey participants expect 75% of companies to see positive AI benefits within the next 3-5 years. Semis, software and data centers are likely to be near-term beneficiaries according to Alkesh Shah. Many of the components needed to build data centers are produced by Alex Virgo's industrial companies. Alec Stranahan thinks AI could reduce inefficiencies within Biotech and could cut the cost of drug development in half. You may also enjoy listening to the Merrill Perspectives podcast, featuring conversations on the big stories, news and trends affecting your everyday financial life. "Bank of America" and “BofA Securities” are the marketing names for the global banking businesses and global markets businesses (which includes BofA Global Research) of Bank of America Corporation. Lending, derivatives, and other commercial banking activities are performed globally by banking affiliates of Bank of America Corporation, including Bank of America, N.A., Member FDIC. Securities, trading, research, strategic advisory, and other investment banking and markets activities are performed globally by affiliates of Bank of America Corporation, including, in the United States, BofA Securities, Inc. a registered broker-dealer and Member of FINRA and SIPC, and, in other jurisdictions, by locally registered entities. ©2023 Bank of America Corporation. All rights reserved.
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today's episode covers a range of news and developments in the industry. Let's get started.## Evelo Biosciences shuts down after clinical setbackFlagship-backed microbiome biotech company Evelo Biosciences is shutting down after facing a clinical setback and laying off staff. The company, which focused on developing microbiome-based therapies, was unable to find a viable alternative to its closure. This news comes as several biotech M&A deals are being announced, although fewer oncology deals have been made this year compared to previous years.## Freeline agrees to take-private deal with SynconaGene therapy company Freeline has agreed to a take-private deal with Syncona after making cuts. This acquisition adds to the string of bargain buyouts and reverse mergers in the gene therapy sector. Meanwhile, fewer biotech companies are going public this year, with only three IPOs taking place in the third quarter. However, there are still many startups waiting in the queue.## Medtronic CEO downplays impact of obesity drugs The CEO of Medtronic, Geoff Martha, downplays the impact of obesity drugs on procedures and devices. Despite the surging demand for GLP-1 agonists, Martha argues that the hit to medtech firms like Medtronic will be minimal.## Index Pharmaceuticals discontinues trial for cobitolimodIndex Pharmaceuticals has decided to discontinue a Phase 3 trial for cobitolimod in ulcerative colitis following a negative review by an independent data monitoring committee. The drug did not meet the primary endpoint of clinical remission compared to placebo.## Moderna's mRNA patent declared invalidThe European Patent Office has declared one of Moderna's mRNA patents invalid, marking a win for Pfizer and BioNTech in ongoing patent disputes between COVID-19 vaccine developers.## CRISPR gene therapy receives approval in the UKCRISPR gene therapy has received its first-ever approval in the UK for the treatment of beta thalassemia. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, this approval raises questions about whether the US FDA will follow suit in approving CRISPR gene therapies.## Digital tools support patients in search for specialistsOver 25% of rare disease patients have to visit multiple hospitals before receiving a diagnosis, and almost half of them wait a year for that diagnosis. Digital tools can play a crucial role in supporting patients in their search for specialists and care. These tools can narrow down the initial search, identify healthcare professionals with the required expertise, and empower patients through tailored resources.## Google and NBCU offer behind-the-scenes look at Macy's Thanksgiving Day ParadeGoogle and NBCU have partnered to offer a behind-the-scenes look at the Macy's Thanksgiving Day Parade through custom ads. The ads feature the Radio City Rockettes and showcase the AI-powered features of Google's Pixel 8 smartphone. Disney and Verizon have also collaborated on an AR experience to support children through donations to Toys for Tots.## Advertising industry falls short of net-zero goalsA report finds that the advertising industry is "not even close" to realizing its net-zero goals in terms of reducing carbon emissions. The slow adoption of sustainability standards among agencies and production companies is having a negative impact on the entire marketing communications supply chain.## Gene editing, mRNA, and cell therapies promise new medicinesThe text discusses the progress in gene editing, mRNA, and cell therapies, highlighting their potential to revolutionize medicine. Funding challenges and an IPO dry spell are acknowledged, but recent investments indicate continued interest and support for biotech innovation.## Merck acquires Caraway TherapeuticsMerck plans to acquire Caraway Therapeutics in a deal worth up to
In an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal structures and strategies that are redefining the biotech investment landscape. Join Chen Yu, Founder & Managing Partner at TCGX, Matthew Young, Managing Director at Longitude Capital, Arsani William, CIO & Managing Partner at Logos Capital, and RBC's Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion exploring how investors across the biotech ecosystem are navigating market complexity to put dollars to work creatively to manage risks, maximize rewards, and stimulate growth.
On this solo episode, I go through a list of 7 books I recommend for med tech, biotech and combination product professionals. The books are: Quality is Free by Phillip Crosby The Combination Products Handbook by Susan Needle What Country has the Best Healthcare by Ezekiel Emanuel Switch by Dan and Chip Heath Managing Oneself by Peter Drucker Bottle of Lies by Katherine Evan The Pyramid Principle by Barbara Minto I find that I read a lot more in December so wanted to give you all some recommendations this Thanksgiving week. Happy Thanksgiving!
In this episode of Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Eva Quinn, Senior Human Resources Business Partner at Higher EQ. Join us as we discuss some of the biggest challenges in biotech HR and what makes it such a unique profession in the industry; the importance of mental health in the workplace; and how HR plays such a vital role in biotech.
Susan Stroud, author of The No Bull newsletter, visits the studio to discuss the challenges in marketing grain and managing risk, stressing the importance of objective analysis and farmers overcoming emotional attachments. She also explores the impact of domestic policies on grain dynamics and competition and emerging trends. -Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.
The overhiring in the technology sector at the end of the pandemic, the resulting layoffs, and the knock-on effects on talent acquisition have been well-documented this year. However, big tech isn't the only area where this has happened. Other talent markets have also been through a similar journey. So how can employers hire more sustainably, and what new talent strategies are companies adopting to build more flexibility? My guest this week is Carina Clingman, Founder and CEO of Recruitomics, a talent consultancy working with start-ups and scale-ups in the Biotech industry. The Biotech industry has had a big issue with overhiring in the last few years. Carina has some insights on sustainable hiring models, which are also relevant in many other sectors. In the interview, we discuss: The changing talent marketing in Biotech Challenging for scaling companies Aligning talent strategies with business goals Fractional hiring Understanding candidate motivations Balancing growth with sustainable hiring The dangers of overhiring What can larger employers learn from start-ups and scale-ups Total talent thinking What is the future for recruiters? Listen to this podcast on Apple Podcasts.
Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in life sciences. This week, we're delighted to be joined by Harry Rickerby, Co-founder of Briefly Bio, a groundbreaking platform he's developing to streamline experimental design in life sciences using large language models (LLMs). Host Ross Katz speaks with Harry about how LLMs are used to facilitate experiment protocol structuring in the platform, the limitations of LLMs in scientific fields, how we can improve collaboration, consistency, and reproducibility in biotech, and how metadata is generated within the experimental design process while interacting with an LLM. --- If you're a biotech company struggling to unlock a data challenge, CorrDyn can help. Whether you need to supplement existing technology teams with specialist expertise or launch a data program that lays the groundwork for future internal hires, you can partner with Corrdyn to unlock the potential of your business data - today. Visit connect.corrdyn.com/biotech to learn more.
Alex Nemiroff took an unusual path to becoming the general counsel at Praxis Precision Medicines. Nemiroff's son was diagnosed with a rare genetic epilepsy, and he co-founded the biotechnology company RogCon to develop an antisense oligonucleotide to treat it. Praxis licensed the project and hired Nemiroff as its general counsel. Now, the company has released encouraging data from the first four evaluable patients in a clinical study of the experimental therapy. We spoke to Nemiroff, general counsel at Praxis Precision Medicines, about his journey as a parent of a child with a rare, genetic disease; how he came to launch a biotechnology company to develop a treatment for his son, and what other patient families looking to advance a therapy can learn from his experience.
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. In our first news, Bayer shares fell by 20% after a study monitors halted a planned 18,000-person trial of its experimental blood thinner drug due to "inferior efficacy" compared to Eliquis. Bristol Myers is also facing a delay from the FDA on a decision regarding its cancer cell therapy. Astrazeneca has created a digital health unit called Evinova to tap into the growing market for digital health solutions. And fewer biotech companies are going public, but Carmot Therapeutics has filed plans to go public in hopes of capitalizing on investor interest in obesity medicines. Janet Woodcock, a top FDA official, will retire early next year after 37 years with the agency.Moving on to our second news, the Federal Trade Commission has filed a lawsuit to block John Muir Health's acquisition of Tenet Hospital, claiming it would reduce competition and increase prices. Mass General Brigham is being sued after potential exposure to HIV and hepatitis at Salem Hospital. Nurses and medical professionals are planning a five-day strike at HCA facilities in southern California. On the other hand, Novant Health plans to buy three Tenet hospitals in South Carolina for $2.4 billion. Telehealth is also highlighted as a growing trend for routine and mental healthcare.Next up, Bayer's investigational factor XIA inhibitor was found to be inferior to Pfizer and BMS' blood thinner Eliquis in a Phase III study. The UK's National Health Service has reached a new deal with pharmaceutical companies that doubles the annual allowed growth in sales of branded medicines. Carmot Therapeutics is planning to make its debut on the NASDAQ stock exchange. Servier is considering filing for FDA approval for its glioma candidate vorasidenib.Lastly, Biohaven aims to develop a novel drug called taldefgrobep alfa that can treat spinal muscular atrophy (SMA) as well as trim fat and build lean muscle mass in obese individuals. Clinical trial diversity has decreased, prompting companies to refine their diversity, equity, and inclusion strategies. The development of new drugs that can address multiple health issues simultaneously shows promise for improving patient outcomes and expanding treatment options.These developments highlight the challenges faced by pharmaceutical companies in developing new drugs and the importance of partnerships between healthcare systems and industry players to advance research and improve patient outcomes.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates.
Obesity affects hundreds of millions of patients in the Western world with the prevalence of obesity in the US at nearly 40%. Given headline-worthy innovations in treatments and subsequent stock moves, investors in pharma and biotech are paying attention. In this episode, Joel Sendek and Jay Olson discuss recent developments in the treatment of obesity, the latest therapies yet to hit the market, and key companies to watch. Podcast Disclosure: This podcast is the property of Oppenheimer & Co. Inc. and should not be copied, distributed, published or reproduced, in whole or in part. The information/commentary contained in this recording was obtained from market conditions and professional sources, and is educational in nature. The information presented has been derived from sources believed to be reliable but is not guaranteed as to accuracy and does not purport to be a complete analysis of any strategy, plan, security, company, or industry involved. Opinions expressed herein are subject to change without notice. Oppenheimer has no obligation to provide any updates or changes. Any examples used in this material are generic, hypothetical and for illustration purposes only. All price references and market forecasts are as of the date of recording. This podcast is not a product of Oppenheimer Research, nor does it provide any financial, economic, legal, accounting, or tax advice or recommendations. Any liability therefore (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. Securities and other financial instruments that may be discussed in this report or recommended or sold are not insured by the Federal Deposit Insurance Corporation and are not deposits or obligations of any insured depository institution. Investments involve numerous risks including market risk, counterparty default risk and liquidity risk. Securities and other financial investments at times maybe difficult to value or sell. The value of financial instruments may fluctuate, and investors may lose their entire principal investment. Prior to making any investment or financial decisions, an investor should seek advice from their personal financial, legal, tax and other professional advisors that take into account all of the particular facts and circumstances of an investor's own situation. The views and strategies described may not be suitable for all investors. This report does not take into account the investment objectives, financial situation or specific needs of any particular client of Oppenheimer or its affiliates. This presentation may contain forward looking statements or projections regarding future events. Forward-looking statements and projections are based on the opinions and estimates of Oppenheimer as of the date of this podcast, and are subject to a variety of risks and uncertainties as well as other factors, including economic, political, and public health factors, that could cause actual events or results to differ materially from those anticipated in the forward-looking statements and projections. Past performance does not guarantee future results. The performance of a benchmark index is not indicative of the performance of any particular investment; however, they are considered representative of their respective market segments. Please note that indexes are unmanaged and their returns do not take into account any of the costs associated with buying and selling individual securities. Individuals cannot invest directly in an index. Oppenheimer Transacts Business on all Principal Exchanges and Member SIPC 6099587.1
This is episode 639. Read the complete transcription on the Sales Game Changers Podcast website. Purchase Fred Diamond's best-sellers Love, Hope, Lyme: What Family Members, Partners, and Friends Who Love a Chronic Lyme Survivor Need to Know and Insights for Sales Game Changers now! Today's show featured an interview with L'areal Lipkins and her client Chelsea Bouvier, Sales Manager at biotech research company Sanguine. IES Women in Sales Program Director Gina Stracuzzi conducted the interview. L'AREAL'S ADVICE: "Slow down to speed up and ask “Where's there a gap?” What's the behavior that's driving that gap? What's the belief that's behind that? What are the behaviors that we're doing or not doing that is generating that on the back end? Is it something cultural that as an organization we have these beliefs around our industry, our product, the economy, whatever it is, that is creating those behaviors or lack thereof, that is getting the results that we're getting or not getting on the back end?" CHELSEA'S ADVICE: "Stay consistent and go in with an open mind if you're changing your sales process. Often, salespeople are close headed, “Hey, it's working,” but you're not always open to, “What else can I do to be better?” You're just scared, what could go wrong? I would certainly say be open and then be consistent."
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. In today's episode, we have several news updates to share with you. Let's get started.## FDA Official Janet Woodcock to RetireJanet Woodcock, a top official at the FDA, will be retiring early next year. Woodcock has been with the agency for an impressive 37 years and has played a crucial role in the FDA's pandemic response. She has also made important decisions regarding opioids, Alzheimer's therapy, and muscular dystrophy drugs.## Homology Enters Reverse Merger with Q32 BioBiotech company Homology has entered a reverse merger with Q32 Bio. This strategic move will result in a combined company operating under Q32's name. Homology recently faced challenges, including staff layoffs and halted research. This merger could potentially help them navigate through these difficulties.## Astellas Acquires Propella TherapeuticsAstellas, a pharmaceutical company, has made a significant acquisition by paying $175 million to acquire privately held Propella Therapeutics. This deal includes an experimental prostate cancer drug. This acquisition reflects the increasing activity in the biotech M&A space.## Eli Lilly Plans $2.5 Billion Manufacturing PlantEli Lilly, a major pharmaceutical company, has announced plans to build a new $2.5 billion manufacturing plant. This facility is aimed at meeting the growing demand for obesity drugs, following the recent approval of their obesity drug, Zepbound. The plant will help prevent shortages and ensure wider access to this drug.## Eli Lilly Invests in German Manufacturing FacilityContinuing on Eli Lilly's expansion plans, they are also investing $2.5 billion in a German manufacturing facility. This investment is specifically focused on meeting the high demand for weight-loss treatments. The German plant will support the supply of Tirzepatide, a drug that has shown promising results in clinical trials for obesity treatment.## AstraZeneca's Truqap Receives FDA ApprovalAstraZeneca's Akt inhibitor, Truqap, has received FDA approval. It can now be used in combination with the endocrine therapy Faslodex for adult patients with advanced HR-positive breast cancer. This approval expands the treatment options for breast cancer patients and provides a new targeted therapy approach.## FDA Approves Pfizer and Astellas' XtandiThe FDA has granted approval for Pfizer and Astellas' Xtandi. This drug can now be used for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis. This approval allows Xtandi to be used earlier in the treatment process, offering a new option for patients with this type of prostate cancer.## Merck's Keytruda Receives Expanded FDA ApprovalMerck has received FDA approval to expand the label of its anti-PD-1 blockbuster drug Keytruda. It can now be used as a first-line treatment option for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. This approval further solidifies Keytruda's position as a leading immunotherapy treatment.## Focus on Disease Prevention in Pharma IndustryThere is a growing conversation around disease prevention in the pharmaceutical industry. Many industry leaders, such as GSK CEO Emma Walmsley and 23andMe CEO Anne Wojcicki, are emphasizing the importance of prevention. GSK is focusing on its pipeline of vaccines, while 23andMe explores the potential of genomics in disease screening. This shift towards prevention comes at a time when life expectancy in the U.S. is declining due to preventable causes.That's all for today's episode. We hope you found these news updates informative and valuable. Stay tuned for more important updates in the Pharma and Biotech world. Thank you for listening to Pharma and Biotech Daily, the podcast that keeps you informed.
From his vantage point as an independent biotech journalist, Luke Timmerman has been watching the expansions and retractions of the industry for a couple of decades now. His unique perspective is hard to equal, and that perspective is, despite tough markets and tepid public sentiment, decidedly bullish. Luke's optimism is fed by sound logic gained from a career spent in observation mode, watching the development of purpose-built tools matched to address the fragility of human biology. Luke's tireless advocacy for the industry also stretches well beyond his professional coverage and punditry. Through his Timmerman Traverse initiative, he's figured out a way to weave his personal and professional passions into a tapestery that serves some of the philanthropic initiatives our industry cares about most. On this episode of the Business of Biotech, we'll get to know Luke personally, we'll learn about his philanthropic work, and we'll give you a healthy dose of optimism as we look ahead to the next decade in biotech. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## The world's first CRISPR medicine, Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, has been approved in the UK for the treatment of sickle cell disease and beta thalassemia. However, a gene editing therapy like CRISPR may not be as simple as it seems. While Casgevy can mute the damaging symptoms of sickle cell disease, treatment may not be straightforward. Red Tree Venture Capital plans to expand into San Diego's biotech pipeline and build a competitor to Boston-area investors. The FDA has approved Augtyro, a new drug developed by Bristol Myers, for the treatment of lung cancer. Astellas has published a paper detailing a gene therapy study that led to patient deaths. The company is working with regulators to lift a clinical hold on the treatment.## The Biden administration has finalized a rule requiring nursing homes to disclose their ownership. CommonSpirit, a nonprofit operator, has started its 2024 fiscal year with a $738 million loss. CMS has proposed stricter network adequacy standards for plans sold in state-run ACA exchanges. Centene, a health insurer, has named Susan Smith as its new Chief Operating Executive. UnitedHealth is being sued for using an algorithm to deny care for Medicare Advantage members. There is an increasing trend of electronic health record (EHR) adoption, which has facilitated the rise of big data in healthcare.## The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted conditional marketing authorization for gene-edited therapy ExA-Cel, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. This marks the world's first approval for a CRISPR-edited therapy. Bristol Myers Squibb's (BMS) drug Augtyro has received FDA approval to treat ROS1-positive non-small cell lung cancer (NSCLC). Astellas sees a path forward for its gene therapy AT132 despite four patient deaths in a clinical trial.## The traditional approach to health marketing is becoming inadequate and less effective compared to biotech and pharmaceutical marketers' expectations. Quad offers next-generation solutions that aim to deliver superior results at a lower cost. The text mentions that Quad has a downloadable resource called "next-gen solutions for health marketing" that covers various topics. Quad also offers advertising opportunities to reach over 96,000 biopharma industry executives.## Influencer marketing is growing at a faster rate than traditional paid social media and is projected to reach $21.2 billion worldwide by 2023. Top retailers are taking note of this trend and using it to shape their strategies for the future. The trendline highlights several examples of how brands are leveraging influencer marketing.## Cognizant's Life Sciences Manufacturing Practice offers resources such as web content, whitepapers, videos, and thought leadership articles on their website. They specialize in creating connected GMP manufacturing and lab systems using digital technology adoption and support.## An infographic discusses the factors and macro-trends that different types of medical device companies need to consider when developing a location strategy. The infographic highlights several macro-trends that companies should take into account when developing their manufacturing strategies.## Finance and procurement professionals in the healthcare industry are encouraged to stay ahead by embracing change and utilizing automation. There is an e-book available that provides tools for success and offers a custom demo for transforming operations management in healthcare organizations.## Novo Nordisk plans to invest $6 billion in expanding its manufacturing capabilities in Denmark. Valneva has received regulatory approval from the FDA for its chikungunya vaccine. The American Medical Association (AMA) has called for broader health insurance coverage f
Episode Description: Alex Rosay of Cascade Biocatalysts joins us as we delve into the groundbreaking realm of enzyme technology and its transformative impact on various industries. We navigate through the innovative world of cell-free biotechnological solutions, highlighting how these advancements are revolutionizing traditional fermentation processes and offering more sustainable, efficient alternatives. We explore the diverse applications of enzymes, from food ingredients to bio-mining, and the challenges and triumphs in stabilizing these biological catalysts. This episode is a fascinating journey into the heart of biotech innovation, showcasing how nature-inspired solutions are shaping a more sustainable industrial future. Grow Everything brings to life the bioeconomy when hosts Karl Schmieder and Erum Azeez Khan share stories from the field and interview leaders and influencers in the space. Life is a powerful force and it can be engineered. What are we creating? Learn more at www.messaginglab.com/groweverything Topics Covered: 00:00 - Meet Alex Rosay and Dive into Enzyme Technology 00:07:48 - The Game-Changing Innovation: Cell-Free Biomanufacturing 00:10:43 - How Biology is Revolutionizing Industries Worldwide 00:11:26 - Insights from Zymergen's Success and Navigating Office Dynamics 00:16:04 - Learning from Zymergen Challenges: Building Stronger Biotech Businesses 00:20:56 - The Scale of Cell-Free Biology: Transforming Manufacturing 00:23:00 - Industry Perspectives on Enhancing Biotech Startups 00:28:30 - Inside Biotech Innovation: Enzyme Production and Stability 00:31:00 - Pioneering Green Technologies: The Next Decade in Biotech 00:36:43 - The Enzymatic Future: Biotech's Role in Brewing and Beyond 00:40:00 - Navigating Startup Challenges: Intellectual Property and Market Competition 00:44:15 - Biological Innovation: Green Materials and Sustainable Industries 00:46:30 - Peering into the Biotech Landscape: Predicting the Next Three Years 00:49:00 - Behind the Scenes: Research and Development in Biotech 00:51:15 - Shaping Traditional Manufacturing with the Power of Biology 00:53:45 - Biotech's Impact on Environmental Sustainability in the Real World Episode Links: LinkedIn Cascade Biocatalysts Have a question or comment? Message us here: Text or Call (804) 505-5553 Instagram / TikTok / Twitter / LinkedIn / Youtube / GrowEverything website Email: firstname.lastname@example.org Support here: Patreon Music by: Nihilore Production by: Amplafy Media --- Send in a voice message: https://podcasters.spotify.com/pod/show/messaginglab/message
Bio-Tech analyst and med-legal advisor Karen Kingston joins us today to discuss whether mRNA manufacturers like Pfizer can be sued for their faulty vaccines. Sun City Silver and Gold: email@example.com Zstack Protocol: https://zstacklife.com/?ref=LAURALYNN ☆ We no longer can trust our mainstream media, which is why independent journalists such as myself are the new way to receive accurate information about our world. Thank you for supporting us – your generosity and kindness to help us keep information like this coming! ☆ ~ L I N K S ~ ➞ DONATE AT: https://www.lauralynn.tv/ or firstname.lastname@example.org ➞ TWITTER: @LauraLynnTT ➞ FACEBOOK: Laura-Lynn Tyler Thompson ➞ RUMBLE: https://rumble.com/c/LauraLynnTylerThompson ➞ BITCHUTE: https://www.bitchute.com/channel/BodlXs2IF22h/ ➞ YOUTUBE: https://www.youtube.com/LauraLynnTyler ➞ TWITCH: https://www.twitch.tv/lauralynnthompson ➞ DLIVE: https://dlive.tv/Laura-Lynn ➞ ODYSEE: https://odysee.com/@LauraLynnTT:9 ➞ GETTR: https://www.gettr.com/user/lauralynn ➞ LIBRTI: https://librti.com/laura-lynn-tyler-thompson
Syngene's MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm's ability to add value in the development and manufacture of ADCs and also its partnership with Amgen are some of the other topics the ex-AstraZeneca executive discusses.
Medical Affairs is going through a digital transformation. What this means, what it will look like, and what value it will bring to pharmaceutical and biotech companies is still unknown. In this third episode of our short form podcast series, we discuss this topic with Christian Dimaano, PhD, MPH. As the VP, Head of Medical Affairs at Kinnate Biopharma, he has a wealth of Medical Affairs experience and insights. This conversation brings us further along in trying to understand the changes that are coming to the industry.
Chinese biotech firms are key players on the international pharmaceuticals market. They produce substances needed to make crucial medicines. That means China has an edge when it comes to both raw materials and technologies.
Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. In today's episode, we'll be discussing some key developments in the industry. First, let's talk about the importance of engaging with healthcare providers before making decisions about recently diagnosed patients. Real-time insights can greatly improve physician outreach, and it's crucial to choose the right data, design the right alerts, and develop a deployment strategy for maximum engagement. A playbook and the expertise of the studioid expert network can provide additional insights and strategies in this area.Next up, Alkermes has separated its cancer drug business and established a new company called Mural Oncology. This move allows Alkermes to reposition itself as a "pure-play" neuroscience company. Gilead Sciences has also expanded its collaboration with Arcellx, a biotech company focused on cancer cell therapies. This partnership gives Gilead an ownership stake in Arcellx and extends their cash runway.Graphite Bio, a gene editing biotech company, has agreed to merge with Lenz Therapeutics after facing financial struggles. This merger comes after layoffs and asset shedding at Graphite Bio. On the other hand, Vectory, a startup backed by Forbion, has raised a significant amount of funding to develop an ALS drug.The American Medical Association (AMA) has introduced new policies targeting coverage for obesity treatment and corporate medicine. They are calling for broader health insurance coverage for obesity treatment, including the use of GLP-1 agonists.Moving on to medical technology, Cardinal's changes to disposable syringes have triggered an FDA recall notice due to delayed therapy and inaccurate dispensing. Vicarious, a surgical robot company, is experiencing delays in development due to integration challenges and cuts in R&D. Stolen Medtronic laryngoscopes have also been recalled, and Abbott's study has linked an aspirin-free regimen to better outcomes in heart pump patients. Lastly, the Biden administration has launched an initiative to accelerate women's health research.In another news, UnitedHealth is being sued for allegedly using an algorithm to deny claims for Medicare Advantage seniors. One Medical has partnered with employer groups to provide primary care services, and state Medicaid officials are projecting a significant drop in enrollment next year. A Senate subcommittee has signaled support for permanent telehealth flexibilities, and there have been recent data breaches in the healthcare industry.Gilead Sciences' subsidiary, Kite, is expanding its collaboration with Arcellx in the development of blood cancer treatments. Alkermes is spinning off its oncology business into a new company called Mural Oncology. Pfizer is set to cut jobs at its UK facility, and Israeli biopharmaceutical executives express concern about the fallout from the conflict in Gaza. Lastly, Sino Biological has developed a cell-free protein synthesis system that has proven effective in overcoming challenges associated with protein production.Lastly, we'll discuss the potential of genomics in healthcare and drug discovery. Anne Wojcicki from 23andMe believes that genomic sequences can provide valuable insight into healthcare needs. Talus Bio, a small biotech company, is using a multidisciplinary platform to map transcription factors for new treatments. Investment in women's health is also on the rise.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more important news and updates in the industry.
This time on Building Biotechs: A Podcast by Recruitomics Consulting, we're joined by Mike LaRhette, Chief Business Officer at LabCentral. We discuss juggling responsibilities in biotech; how biotechs are saving the human race; the most important components of an entrepreneurial ecosystem; and some of the biggest obstacles when working with partners.
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Today, we have a packed episode with news from the marketing and biotech sectors.In the marketing world, Chili's is making a nostalgic move by remixing its famous jingle with Boyz II Men. The campaign plays on the misconception that the group was behind the jingle when it first became popular in the 90s. Meanwhile, Lego is using augmented reality (AR) to host a snowball throwing contest at its flagship stores in New York and London. Shoppers will compete to see which city can throw the most digitized snowballs. Lay's and former "The Bachelor" star Matt James are getting in on a viral cooking hack of turning chips into mashed potatoes. They are running a social media sweepstakes to promote their cookbook kit. Trade Desk, an advertising technology company, has reported strong Q3 earnings as its Unified ID 2.0 (UID2) gains momentum. However, the company's shares dropped due to lower Q4 guidance based on advertiser caution. Lastly, alcohol e-commerce platform Drizly is launching a game show campaign and gift registry to meet evolving consumer habits.Now, moving on to biotech news. Ajinomoto, a Japanese food and biotechnology company, has partnered with Forge Biologics in the gene therapy space. Cargo Therapeutics, a CAR-T biotech company, has priced its IPO at $281 million. However, there are concerns about the viability of using CRISPR as a cure for genetic diseases like sickle cell disease. While a therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics has shown promise in muting the symptoms of sickle cell disease, there are complexities and challenges that need to be addressed. In an interview, 23andMe CEO Anne Wojcicki discusses how the company is expanding into drug research and development. Finally, there has been a decline in the number of biotech companies going public, with fewer IPOs in recent years. This trend is seen as oncology-focused drugmakers dominate new biotech stock offerings.That wraps up today's episode of Pharma and Biotech Daily. Stay tuned for more important news and updates in the world of Pharma and Biotech. Have a great day!
This week Pat Holterman-Hommes visits the studio, CEO of Youth in Need, an organization helping at-risk youth, especially those experiencing homelessness. They go into the complex reasons youth become homeless, difficulties faced by homeless youth, and societal misunderstandings about LGBTQ+ youth and the impact on mental health.Website: www.youthinneed.org-Book a Legacy Interview | https://legacyinterviews.com/ —A Legacy Interview is a two-hour recorded interview with you and a host that can be watched now and viewed in the future. It is a recording of what you experienced, the lessons you learned and the family values you want passed down. We will interview you or a loved one, capturing the sound of their voice, wisdom and a sense of who they are. These recorded conversations will be private, reserved only for the people that you want to share it with.
I recorded this episode in Delhi - what a time to record! We started with the impact of AQI on lifespan & talk about the impact of pincode on your lifespan. Longevity feels like a field where you need to spend a ton of time in research but Alex shared his views on how we can get started with a lot less. It was interesting to get his thoughts on how young people are approaching the field & the progress we've already made. The contribution of Age1 has been quite phenomenal in the field & their dedication to help more people get started. I've a lot of homework to do in the field & I find it quite exciting. I hope this episode can convince you to get started as well. Here's a good place to start reading in case you're curious: https://www.timeinitiative.org/resources
When Maria Picone's daughter was diagnosed with Prader-Willi Syndrome (PWS), she turned to the internet for answers. What she found was an online community of caregivers sharing their experiences with PWS, giving her comfort and direction with what to do about her daughter's rare disease. It also spurred her and her husband to create TREND Community, an online platform for caregivers of rare diseases to not only share their experiences, but also make positive contributions to scientific literature. Join us as we discuss the philosophy of TREND Community, how it transforms general discussions into real-world clinical research, how collaboration drives their progress, what's next for TREND, and what you can do to help advance their mission. Show Notes Trend Community - Impact Through InsightsTrend Community Report on Identifying Mental Health Challenges Experienced by Caregivers in Rare Disease Communities: A Social Media AnalysisCharles River | Rare DiseaseThe Disruptors: Innovation in Drug Discovery
Our reluctant heroes find themselves at an abandoned factory for Exos Biotech. This is where the clues have led them. But the Exos Corporation doesn't work in Biotech... The secrets the uncover here will change everything. Learn more about your ad choices. Visit megaphone.fm/adchoices
Earlier this year, Shawn Davis, Ph.D. left a pretty comfortable position at AstraZeneca (and Amgen before that, and Milliken, and others, before that) to lead Liberate Bio. He brought along another industry notable in Merck/Intellia alumnus Walter Strapps, Ph.D., who serves as CSO at Liberate. Why'd they do it? Because RNA delivery is such a crucial step toward revolutionary genetic medicine, but it's tough science. They think they can change that. On this episode of the Business of Biotech, Drs. Davis and Strapps share how they're applying automation and machine learning technologies to minimize the challenges associated with targeted delivery of genetic medicine and overcome the limitations of AAV. During our conversation, they both leaned hard into how their previous experiences have shaped the work they're doing, and the wide-open business opportunities Liberate Bio is creating. Subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!
Dive into the vibrant intersection of cannabis culture and industry innovation with Niko Sosiak from Cannara Biotech, a visionary in the Canadian cannabis space. This discussion isn't just another chat about cannabis; it's a deep dive into how one man's passion for the plant has bloomed into a thriving business, paving the way for new industry standards. Niko shares his evolution from a longtime user to a key player in the market, highlighting his commitment to creating straightforward, user-friendly cannabis products that cater to both connoisseurs and newcomers. The episode gives listeners a behind-the-scenes look at the challenges and triumphs of navigating the legal cannabis industry. It offers a unique blend of personal anecdotes and professional insights, revealing how Niko's approach has led to the creation of products that are both innovative and deeply respectful of the cannabis community's roots. Learn about Cannara Biotech's distinctive branding strategy for their different lines, including Tribal Nugs and Orchid CBD, and how Niko's creative vision as CFO has been integral to their development. This episode is essential for anyone looking to understand the synthesis of individual passion with professional ambition, delivering a narrative that subtly underscores the transformative power of dedication and innovation in the entrepreneurial journey.
Viraj Mane is the co-founder & Chief Scientific Officer at Lactiga, an award-winning, venture-backed biotherapeutics company treating and prevent infections using an unusual but genius method…human milk. That's right, Lactiga uses human breast milk to battle even the world's most dangerous pathogens. It turns out, some people would benefit tremendously from what's found in the breast milk of other humans, and if done right, the power of this novel approach is astounding. Viraj has a PhD in Human Genetics from Baylor College of Medicine, and has completed two post-doc fellowships, including one for the U.S. FDA. After he became a father, he had a strange but brilliant idea after seeing excess breast milk stored in the freezer. I know you'll love this episode from a very smart person. ➡️ https://lactiga.com/ ➡️ https://rosspalmer.com/viraj-mane ➡️ Follow me on Instagram: @therosspalmer ➡️ Subscribe on YouTube: @therosspalmer